Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 25.9% year on year to $266 million. On the other hand, the company’s full-year revenue guidance of $1.11 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $2.21 per share was 8.2% above analysts’ consensus estimates.

Is now the time to buy ANI Pharmaceuticals? Find out by accessing our full research report, it’s free.

“In the second quarter, we delivered outstanding financial results, while we implemented the largest Rare Disease sales force expansion in our history,” said Nikhil Lalwani, President and CEO of ANI.

Company Overview

With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ:ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, ANI Pharmaceuticals grew its sales at an incredible 35.6% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. ANI Pharmaceuticals’s annualized revenue growth of 34.7% over the last two years aligns with its five-year trend, suggesting its demand was predictably strong.

This quarter, ANI Pharmaceuticals reported robust year-on-year revenue growth of 25.9%, and its $266 million of revenue topped Wall Street estimates by 2.4%.

Looking ahead, sell-side analysts expect revenue to grow 23.3% over the next 12 months, a deceleration versus the last two years. Despite the slowdown, this projection is commendable and indicates the market is baking in success for its products and services.

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.

Adjusted Operating Margin

ANI Pharmaceuticals has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 24.5%.

Analyzing the trend in its profitability, ANI Pharmaceuticals’s adjusted operating margin rose by 10 percentage points over the last five years, as its sales growth gave it operating leverage. Zooming into its more recent performance, however, we can see the company’s margin has decreased by 1 percentage points on a two-year basis. Given its business quality, we’re optimistic that ANI Pharmaceuticals can correct course and return to expansion.

In Q2, ANI Pharmaceuticals generated an adjusted operating margin profit margin of 19.5%, down 6.1 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

ANI Pharmaceuticals’s EPS grew at an astounding 19.9% compounded annual growth rate over the last five years. Despite its adjusted operating margin improvement during that time, this performance was lower than its 35.6% annualized revenue growth, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings.

Diving into ANI Pharmaceuticals’s quality of earnings can give us a better understanding of its performance. A five-year view shows ANI Pharmaceuticals has diluted its shareholders, growing its share count by 81.3%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, ANI Pharmaceuticals reported adjusted EPS of $2.21, up from $1.80 in the same quarter last year. This print beat analysts’ estimates by 8.2%. Over the next 12 months, Wall Street expects ANI Pharmaceuticals’s full-year EPS to grow 14.9% from $8.63 to $9.92.

Key Takeaways from ANI Pharmaceuticals’s Q2 Results

It was encouraging to see ANI Pharmaceuticals beat analysts’ revenue expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its full-year revenue guidance slightly missed. Zooming out, we think this was a mixed quarter. Investors were likely hoping for more, and shares traded down 7.4% to $76.53 immediately after reporting.

Is ANI Pharmaceuticals an attractive investment opportunity right now? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).